Comparison of efficacy and safety of 0.01% Bimatoprost and 0.1%Tacrolimus in the treatment of facial vitiligo

Not Applicable

Recruiting

• Conditions: - facial vitiligo patient; vitiligo; bimatoprost; protopic

• Registration Number: TCTR20161008001
• Lead Sponsor: Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-08
• Study Completion: 2017-01-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

- facial vitiligo patient
- other affected vitiligo area less than 2% BSA

Exclusion Criteria

- apply topical steroid within 7 days
- on current medication effected skin pigmentation within 2 weeks
- on current treatment of vitiligo such as oral medication, NBVUB, PUVA, systemic steriod within 1 month
- allergy to bimatoprost and protopic
- pregnancy and breast feeding patient
- underlying disease: asthma

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
compare efficacy of 0.01%bimatoprost to 0.1%protopic 1,2,3 month percent repigmentation and are of repigmentation

Secondary Outcome Measures

Name	Time	Method
safety of 0.01%bimatoprost 1,2,3 month check list for side effect